pirinixic acid has been researched along with Dyslipidemias in 4 studies
pirinixic acid: structure
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 7.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| "05) by treatment with 300 mg fenofibrate once daily for 4 weeks in 13 patients with dyslipidemia." | 3.77 | Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets. ( Abe, M; Aihara, K; Akaike, M; Azuma, H; Hashizume, S; Ikeda, Y; Ishikawa, K; Iwase, T; Matsumoto, T; Sata, M; Sumitomo-Ueda, Y; Yagi, S; Yoshida, S, 2011) |
| " The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its lipid-lowering effect is mediated through its activation of PPARalpha." | 3.73 | The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. ( Chen, YT; Li, PP; Liu, Q; Lu, XP; Ning, ZQ; Shan, S; Shen, ZF; Sun, SJ; Xie, MZ, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashizume, S | 1 |
| Akaike, M | 1 |
| Azuma, H | 1 |
| Ishikawa, K | 1 |
| Yoshida, S | 1 |
| Sumitomo-Ueda, Y | 1 |
| Yagi, S | 1 |
| Ikeda, Y | 1 |
| Iwase, T | 1 |
| Aihara, K | 1 |
| Abe, M | 1 |
| Sata, M | 1 |
| Matsumoto, T | 1 |
| Li, PP | 1 |
| Shan, S | 1 |
| Chen, YT | 1 |
| Ning, ZQ | 1 |
| Sun, SJ | 1 |
| Liu, Q | 1 |
| Lu, XP | 1 |
| Xie, MZ | 1 |
| Shen, ZF | 1 |
| Lanne, B | 2 |
| Dahllöf, B | 1 |
| Lindahl, C | 1 |
| Ebefors, K | 1 |
| Kanmert, I | 1 |
| von Bahr, H | 1 |
| Miliotis, T | 1 |
| Nyström, AC | 1 |
| Arnerup, G | 1 |
| Paulsons, I | 1 |
| Kerb, S | 1 |
| Oakes, N | 1 |
| Sheikh, K | 1 |
| Camejo, G | 1 |
| Halvarsson, T | 1 |
| Landergren, MR | 1 |
| Oakes, ND | 1 |
4 other studies available for pirinixic acid and Dyslipidemias
| Article | Year |
|---|---|
Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.
Topics: Adult; Becaplermin; Blood Platelets; Cell Differentiation; Cell Line, Tumor; Dyslipidemias; Female; | 2011 |
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats.
Topics: Adipose Tissue; Animals; Blood Glucose; Carbazoles; Disease Models, Animal; Dyslipidemias; Gene Expr | 2006 |
PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
Topics: Adipose Tissue; Animals; Dyslipidemias; Hypoglycemic Agents; Liver; Male; Mice; Mice, Obese; Peroxis | 2006 |
Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat.
Topics: Amino Acids; Animal Feed; Animals; Chromatography, High Pressure Liquid; Dietary Fats; Dyslipidemias | 2007 |